©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Oct 10, 2018; 7(6): 117-122
Published online Oct 10, 2018. doi: 10.5527/wjn.v7.i6.117
Published online Oct 10, 2018. doi: 10.5527/wjn.v7.i6.117
Oral alkali therapy and the management of metabolic acidosis of chronic kidney disease: A narrative literature review
Adeel Rafi Ahmed, David Lappin, Department of Nephrology, University Hospital Galway, Galway H91YR1, Ireland
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Correspondence to: Adeel Rafi Ahmed, MBChB, MRCP, Staff Physician, Department of Nephrology, University Hospital Galway, Newcastle Road, Galway H91YR1, Ireland. adeel.r.ahmed@gmail.com
Telephone: +353-86-2350526
Received: May 7, 2018
Peer-review started: May 7, 2018
First decision: May 25, 2018
Revised: July 14, 2018
Accepted: August 30, 2018
Article in press: August 30, 2018
Published online: October 10, 2018
Processing time: 157 Days and 8.2 Hours
Peer-review started: May 7, 2018
First decision: May 25, 2018
Revised: July 14, 2018
Accepted: August 30, 2018
Article in press: August 30, 2018
Published online: October 10, 2018
Processing time: 157 Days and 8.2 Hours
Core Tip
Core tip: Chronic metabolic acidosis contributes to the progression of chronic kidney disease (CKD). We summarise and analyse current evidence regarding the management of the metabolic acidosis of CKD, as well as the potential benefits and adverse effects. We also offer novel therapeutic guidelines for clinicians, which include the most evidence-based range to maintain serum bicarbonate in the CKD patient population.